Alto Neuroscience’s Post

Listen in as our CEO Amit Etkin and NAMI Montana executive director Matt Kuntz discuss how we are combatting trial-and-error in #psychiatry through our precision drug development approach and patient advocacy initiatives in this NBC Montana segment: https://bit.ly/3XR05e3

#DYK that the prevalence of major depressive episodes is highest among individuals who report having multiple (two or more) races? This National #MinorityMentalHealth Awareness Month let's raise awareness and break the stigma around #MentalHealth in minority communities. Check out this episode of NAMI's podcast discussing the importance of minority mental health: https://bit.ly/4btXKsr #ShadesofMentalHealth

We are excited to share that our company is now included in the Russell 2000® Index and Russell 3000® Index, effective today! Learn more about this milestone and the Russell Indexes: https://lseg.group/4eLqu2M #RussellReconstitution $ANRO

Our team had a blast getting together for Alto's annual summer event. Between the engaging Town Hall meeting, breakout discussions, team-building activities, and socializing after work, the Alto core value of #InThisTogether was well represented this week. Until next time! 🎉

🤝 In case you missed us at the 2024 BIO International Conference, our CEO Amit Etkin participated in a panel discussion on #neuropsychiatric drug development and the future of innovation in #CNS. Watch here: https://bit.ly/3KZe2im #BIO2024

Our Precision Psychiatry Platform™ leverages the richest human data sets and is built on a decade of clinical #neuroscience research. Constantly iterating on what we discover, our platform enables us to harness the power of #AI driven brain #biomarkers to match patients with the right Alto drugs in development. Learn more about our platform here: https://bit.ly/4efTm32

We're pleased to announce the initiation of our Phase 2 study of ALTO-101, a novel PDE4 inhibitor in development for the treatment of cognitive impairment associated with #schizophrenia. Learn more here: https://bit.ly/4etQaAW

🏆 We are proud to share that our CEO, Amit Etkin, has been named a 2024 EY Entrepreneur Of The Year Bay Area winner! This prestigious award recognizes his visionary leadership, innovation, and unwavering commitment to catalyzing meaningful change in #MentalHealth treatment through #PrecisionPsychiatry. We look forward to continued growth at Alto under his guidance. Read more here: https://bit.ly/45LB3z3

👥 The past few decades have seen stunning medical breakthroughs, but very little progress has been made in #MentalHealth. Every person’s brain reacts to medications differently, which is why taking a #PrecisionPsychiatry approach, where each patient is matched with the right Alto drug in development for their unique biology, is vital for creating meaningful impact. See how we're working to redefine #psychiatry: https://bit.ly/3z6wWRu